Trial Profile

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Nov 2024 According to an Ascentage Pharma media release, data from this trial to be presented, at the 66th American Society of Hematology (ASH) Annual Meeting. The 66th ASH Annual Meeting will take place on Dec 7-10, 2024, local time, both online and in-person in San Diego, CA (United States).
30 Jan 2024 Status changed from not yet recruiting to recruiting.
27 Nov 2023 Planned initiation date changed from 20 Oct 2023 to 20 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com